Cytori (CYTX) Q2/12 Investor conference call results on 8/8/12 Read more…
Sistemic has formed a customer relationship with Cytori Therapeutics (CYTX), Read more…
To launch product line for plastic surgery and select soft tissue therapies Read more…
Net loss was $9.3M, or $0.16 per share Read more…
CYTX has received 510(k) clearance from the FDA for the Puregraft(R) 850 System for body contouring using a patient’s own fat. Read more…
CFO of Cytori Therapeutics Inc (CYTX) Mark E Saad buys 10,000 shares
CYTX achieved important objectives Read more…
Net loss for Q4/11 was $6.9M or ($0.12) per share Read more…
Christopher J Calhoun, Cytori (CYTX) CEO, Sells 205,000 shares Read more…
CYTX has been issued US Patent No. 8,105,580, covering Methods of using Adipose-derived Stem and Regenerative cells Read more…
Founder and Director of Research, Henry McCusker enters his tenth (10) year at Scimitar Equity with past experience in sell-side analysis, buy-side management, corporate management and due diligence.
I started this blog to add commentary, update news flow and insightful opinions that are intelligent, fit to print and SEC compliant.